ArticleCancer biomarkers : section A of Disease markers2025
A nomogram based on the 3-gene signature and clinical characteristics for predicting lymph node metastasis in papillary thyroid cancer.
Article in Cancer biomarkers : section A of Disease markers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A seven-gene diagnostic and prognostic signature for papillary thyroid carcinoma.Discover oncology · 2026Article
- Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundPrecise recognition of neck lymph node metastasis (LNM) is essential for choosing the suitable scope of operation for papillary thyroid cancer(PTC) patients.ObjectiveThe purpose of our study was to establish an effective nomogram integrating both gene biomarkers and clinicopathologic features for preoperatively predicting LNM in PTC patients.MethodsWe gathered clinical information and gene expression data for PTC samples from The Cancer Genome Atlas database (TCGA). WGCNA and differential analysis were applied to identify LNM-related differentially expressed genes in PTC patients. We developed a risk score based on the 3-gene signature predicting LNM using the LASSO regression analysis. Furthermore, multivariate logistic regression analysis was performed to establish a nomogram. We evaluated the discriminative ability of the nomogram by calculating the area under the ROC curve. Besides, we applied the decision curve analyses and calibration curve to assess the nomogram's actual benefits and accuracy.ResultsSignificant predictors of LNM in PTC patients were eventually screened to develop a nomogram, which included age, histological type, focus type, T stage, and risk score calculated based on IQGAP2, BTBD11 and MT1G expression levels. The AUC value of the nomogram for training and validation set was 0.802 (95% CI 0.750-0.855) and 0.718 (95% CI 0.624-0.811). Moreover, the nomogram has outstanding calibration and actual clinical patient benefits.ConclusionsWe identified a nomogram based on the 3-gene signature and clinical characteristics that effectively predicted LNM in PTC patients, which offers guidance for the preoperative assessment the appropriate scope of operation in PTC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.